- Report
- February 2025
- 200 Pages
Global
From €4096EUR$4,490USD£3,501GBP
- Drug Pipelines
- July 2024
- 150 Pages
Global
From €3421EUR$3,750USD£2,924GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1368EUR$1,500USD£1,170GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1368EUR$1,500USD£1,170GBP
- Clinical Trials
- April 2024
- 75 Pages
Global
From €1368EUR$1,500USD£1,170GBP
- Report
- April 2025
- 50 Pages
Global
From €2417EUR$2,650USD£2,066GBP
Nicardipine is a calcium channel blocker used to treat hypertension and angina. It is a cardiovascular drug that works by relaxing the blood vessels, allowing blood to flow more easily and reducing the workload on the heart. Nicardipine is also used to prevent chest pain caused by coronary artery spasm. It is available in both oral and intravenous formulations.
Nicardipine is a widely used drug in the cardiovascular market, with a variety of formulations available. It is generally well tolerated and has a low risk of side effects. It is also cost-effective, making it an attractive option for many patients.
Companies in the Nicardipine market include Pfizer, Novartis, Sanofi, Merck, and GlaxoSmithKline. Show Less Read more